Following confirmation that these structural deficits were recapitulated in multiple hormone-expressing tumor cell lines, we investigated whether these clinically defined MEN1 mutations and variant confer pathogenic properties by inhibiting the tumor-suppressive function of wild-type menin. This evidence concerns the gene MEN1 and neoplasm.